These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31794942)

  • 1. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of an isogenic gene-corrected iPSC line (PUMCHi001-A-1) from a familial partial lipodystrophy type 2 (FPLD2) patient with a heterozygous R349W mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Apr; 44():101753. PubMed ID: 32213461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C.
    Cecchetti C; D'Apice MR; Morini E; Novelli G; Pizzi C; Pagotto U; Gambineri A
    Front Endocrinol (Lausanne); 2021; 12():675096. PubMed ID: 33953703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA.
    Thong KM; Xu Y; Cook J; Takou A; Wagner B; Kawar B; Ong AC
    Nephron Clin Pract; 2013; 124(1-2):31-7. PubMed ID: 24080738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput Second-generation Sequencing Technology Assisted Diagnosis of Familial Partial Lipodystrophy (Type 2 Kobberling-Dunnigan Syndrome): A Case Report.
    Deng M; Chen W; Qi Y
    Comb Chem High Throughput Screen; 2024; 27(2):346-351. PubMed ID: 37231758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).
    Lanktree M; Cao H; Rabkin SW; Hanna A; Hegele RA
    Clin Genet; 2007 Feb; 71(2):183-6. PubMed ID: 17250669
    [No Abstract]   [Full Text] [Related]  

  • 16. Familial partial lipodystrophy presenting as metabolic syndrome.
    Chan D; McIntyre AD; Hegele RA; Don-Wauchope AC
    J Clin Lipidol; 2016; 10(6):1488-1491. PubMed ID: 27919367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
    Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe loss of adipose tissue in a Vietnamese lipodystrophy patient caused by
    Vu NP; Tran HT; Vu NB; Ma TTH; Nguyen TD; Nong HV; Nguyen HH
    J Pediatr Endocrinol Metab; 2022 Sep; 35(9):1206-1210. PubMed ID: 35822709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.